We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Touts Keytruda’s Ability to Prevent Resurgence of Early-Stage Breast Cancer
Merck Touts Keytruda’s Ability to Prevent Resurgence of Early-Stage Breast Cancer
Merck said its blockbuster cancer drug Keytruda (pembrolizumab) has become the first immunotherapy to succeed in stopping the return of tumors in patients with an aggressive form of early-stage breast cancer.